Loading...
Loading...
TERN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.2M |
| Gross Profit | -0.2M |
| Operating Expense | 25.3M |
| Operating I/L | -25.5M |
| Other Income/Expense | 2.9M |
| Interest Income | 2.9M |
| Pretax | -22.7M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -22.7M |
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company's product pipeline includes TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, TERN-201, a vascular adhesion protein-1 inhibitor, TERN-501, a thyroid hormone receptor beta agonist, and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program. These products are in various stages of clinical trials and are intended for the treatment of NASH and metabolic diseases, such as obesity.
